Latest

T cells

Long-term Clinical Outcomes With Tisagenlecleucel in High-risk Relapsed/refractory Follicular Lymphoma

A new study published in the Haematologica journal provides four-year follow-up results on the efficacy, safety, and pharmacokinetics of tisagenlecleucel treatment for patients with relapsed/refractory follicular lymphoma. The study, led by researchers from the University Teaching Hospital, demonstrates robust and durable responses with tisagenlecleucel and a favorable safety profile,